Text Size
26 studies found for:    "Exostoses, Multiple Hereditary" OR "Osteochondroma" OR "Osteochondromatosis" OR "hereditary multiple exostoses"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses
Condition: Exostoses, Multiple Hereditary
Intervention:
2 Recruiting Gene Mutations and Orthopaedic Symptoms Correlation of Multiple Hereditary Exostoses: Multicentre Project
Condition: Exostoses, Multiple Hereditary
Intervention:
3 Terminated Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC
Condition: Exostoses, Multiple Hereditary
Intervention:
4 No longer available Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) Ext 1
Condition: Lymphoma, T-Cell, Cutaneous
Intervention: Drug: Comparator: vorinostat
5 Active, not recruiting A Study of V503 in Preadolescents and Adolescents (V503-002 EXT1 EXT2)
Conditions: Cervical Cancers;   Vulvar Cancer;   Vaginal Cancer;   Genital Lesions;   PAP Test Abnormalities;   HPV Infections
Intervention: Biological: V503
6 Active, not recruiting Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041 AM1 EXT1)
Condition: HPV Infections
Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine;   Biological: Comparator: placebo (unspecified)
7 Completed
Has Results 		Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007 EXT1)(COMPLETED)
Condition: Pneumococcal Infection
Intervention: Biological: pneumococcal 23v polysaccharide vaccine
8 Active, not recruiting A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM4 EXT 1)
Condition: Rheumatoid Arthritis
Interventions: Biological: MK-8808 500 mg/m^2;   Biological: Rituximab 500 mg/m^2;   Drug: Methotrexate;   Biological: MabThera (rituximab) 500 mg/m^2;   Biological: Rituxan (rituximab) 500 mg/m^2;   Biological: MK-8808 1000 mg
9 Completed
Has Results 		Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Condition: Multiple Myeloma
Interventions: Drug: vorinostat;   Drug: bortezomib
10 Completed Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001 EXT1)(COMPLETED)
Condition: Pneumococcal Vaccines
Interventions: Biological: Adults-Adjuvanted V114;   Biological: Adults-Prevnar™;   Biological: Toddlers-Adjuvanted V114;   Biological: Toddlers-Non-adjuvanted V114;   Biological: Toddlers-Prevnar™
11 Completed A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1[AM3])
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo;   Drug: pioglitazone;   Drug: metformin
12 Completed Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)
Conditions: Mesothelioma;   Lung Cancer
Interventions: Drug: vorinostat;   Drug: Placebo
13 Active, not recruiting A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018 AM5, EXT1)
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Odanacatib;   Drug: Placebo for Odanacatib;   Dietary Supplement: Vitamin D3
14 Completed
Has Results 		Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Condition: Lymphoma
Intervention: Drug: vorinostat
15 Active, not recruiting
Has Results 		Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015 AM5; EXT1; EXT2(AM1))
Conditions: Cervical Cancer;   Genital Warts
Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine;   Biological: Matching Placebo
16 Completed
Has Results 		An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
Condition: Proteinuria
Interventions: Drug: Losartan Potassium;   Other: Comparator: Placebo (Losartan);   Drug: Comparator: amlodipine besylate;   Other: Comparator: Placebo (amlodipine besylate);   Other: Placebo (Losartan);   Drug: Enalapril Maleate
17 Completed
Has Results 		Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Conditions: Leukemia, Myelocytic, Acute Myelodysplastic Syndromes;   Myelodysplastic Syndromes
Interventions: Drug: vorinostat;   Drug: decitabine
18 Terminated
Has Results 		Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: MK-0941;   Drug: Comparator: Placebo;   Biological: Lantus;   Drug: Metformin
19 Active, not recruiting A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2])
Condition: Urinary Bladder, Overactive
Interventions: Drug: MK-4618 low-dose;   Drug: MK-4618 mid-low dose;   Drug: MK-4618 mid-high dose;   Drug: tolterodine ER;   Drug: Placebo for MK-4618;   Drug: Placebo for tolterodine ER;   Drug: MK-4618 high dose
20 Active, not recruiting
Has Results 		A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019 AM4, EXT1, EXT2 [AM1])
Conditions: Healthy;   Papillomavirus Infection
Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine;   Biological: Comparator: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results
† Indicates status has not been verified in more than two years